MedTrace Logo

A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19

NCT04770467 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-03-03

No results posted yet for this study

Summary

This study is to evaluate the safety, efficacy and pharmacokinetics profile of human monoclonal antibodies, BRII-196 and BRII-198 compared with placebo in patients with COVID-19.

Conditions

Interventions

DRUG

BRII-196 and BRII-198

BRII-196 and BRII-198 given by intravenous administration

DRUG

Placebo

Placebo given by intravenous administration

Sponsors & Collaborators

  • Brii Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Yao Zhang, MD · Brii Biosciences, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-28
Primary Completion
2022-10-31
Completion
2022-10-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04770467 on ClinicalTrials.gov